Charles River Laboratories International Inc operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Charles River Laboratories International Inc with three other
companies in this sector in the United States:
sales of $1.88 billion
of which 100%
was Drug Discovery & Development),
of which 70%
was CABOMETYX), and
PRA Health Sciences Inc
of which 91%
was Clinical Research).
During the year ended December of 2018, sales at
Charles River Laboratories International Inc were $2.27 billion.
increase of 22.0%
versus 2017, when the company's sales were $1.86 billion.
This was the fifth consecutive year of sales increases at Charles River Laboratories International Inc
(and since 2013, sales have increased a total of 94%).
Sales of Discovery and Safety Assessment saw an increase
34.4% in 2018, from
$980.02 million to $1.32 billion.